Jefferies Group LLC reaffirmed their buy rating on shares of NantHealth Inc (NYSE:NH) in a report issued on Thursday. They currently have a $5.00 target price on the stock.

Several other research firms also recently weighed in on NH. Canaccord Genuity reissued a buy rating and set a $6.00 price target (down previously from $8.00) on shares of NantHealth in a research report on Monday, August 21st. BidaskClub raised NantHealth from a sell rating to a hold rating in a research report on Friday, September 15th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $8.55.

Shares of NantHealth (NH) opened at 4.12 on Thursday. The stock’s market capitalization is $502.42 million. NantHealth has a 12 month low of $4.00 and a 12 month high of $13.96. The company’s 50 day moving average price is $4.41 and its 200 day moving average price is $4.41.

NantHealth (NYSE:NH) last released its quarterly earnings data on Thursday, August 10th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.32). NantHealth had a negative net margin of 267.11% and a negative return on equity of 83.97%. The firm had revenue of $26.23 million during the quarter, compared to analysts’ expectations of $31.28 million. During the same period in the previous year, the business earned ($0.15) earnings per share. The business’s revenue for the quarter was down 16.7% on a year-over-year basis. Equities analysts anticipate that NantHealth will post ($0.70) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Jefferies Group LLC Reaffirms Buy Rating for NantHealth Inc (NH)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/10/01/jefferies-group-llc-reaffirms-buy-rating-for-nanthealth-inc-nh.html.

A number of institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System increased its position in NantHealth by 132.4% during the second quarter. California State Teachers Retirement System now owns 31,600 shares of the company’s stock worth $134,000 after buying an additional 18,000 shares in the last quarter. State Street Corp increased its position in NantHealth by 88.1% during the second quarter. State Street Corp now owns 147,234 shares of the company’s stock worth $623,000 after buying an additional 68,963 shares in the last quarter. Goldman Sachs Group Inc. increased its position in NantHealth by 91.5% during the second quarter. Goldman Sachs Group Inc. now owns 169,603 shares of the company’s stock worth $717,000 after buying an additional 81,024 shares in the last quarter. Vanguard Group Inc. increased its position in NantHealth by 20.2% during the second quarter. Vanguard Group Inc. now owns 423,537 shares of the company’s stock worth $1,792,000 after buying an additional 71,087 shares in the last quarter. Finally, Northern Trust Corp increased its position in NantHealth by 133.9% during the second quarter. Northern Trust Corp now owns 151,907 shares of the company’s stock worth $643,000 after buying an additional 86,955 shares in the last quarter.

NantHealth Company Profile

NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

Receive News & Stock Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related stocks with our FREE daily email newsletter.